logo
logo
Teladoc Health, Inc.

Teladoc Health, Inc.

NYSE•TDOC
CEO: Ms. Mala Murthy
セクター: Healthcare
業種: Medical - Healthcare Information Services
上場日: 2015-06-30
Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.
連絡先情報
2 Manhattanville Road, Suite 203, Purchase, NY, 10577, United States
203-635-2002
www.teladochealth.com
時価総額
$860.75M
PER (TTM)
-3.8
30
配当利回り
--
52週高値
$15.21
52週安値
$4.70
52週レンジ
1%
順位66Top 96.8%
1.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$626.44M-2.20%
直近4四半期の推移

EPS

-$0.28+40.00%
直近4四半期の推移

フリーCF

$67.95M-14.02%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Significant Net Loss Improvement Nine months net loss improved $777.66M to $(175.18M), reflecting reduced goodwill impairment charges year-to-date.
Revenue Stability Post-Acquisitions Total revenue $1.89B for nine months; Integrated Care revenue grew 3% despite overall 2% decline.
Strong Cash Position Maintained Cash reserves total $726.25M; operating cash flow stable at $206.62M for the nine months period.
BetterHelp Margin Compression BetterHelp Adjusted EBITDA fell 58% to $23.42M for nine months due to paying user declines.

リスク要因

BetterHelp Profitability Decline BetterHelp Adjusted EBITDA dropped 58% to $23.42M for nine months due to user declines.
Goodwill Impairment Potential Integrated Care goodwill impairment risk remains if carrying value exceeds fair value post-acquisitions.
CFO Leadership Transition CFO Mala Murthy resigned; CEO Charles Divita III assumes interim CFO duties until replacement found.
Restructuring Cost Recognition Expect charges recognized in Q4 2025 related to efficiency initiatives optimizing operational costs and branding.

見通し

Efficiency Initiative Implementation Evaluating initiatives to improve efficiency; expecting to begin recognizing related restructuring charges in Q4 2025.
Cash Sufficiency Expected Existing cash sufficient to meet working capital and CapEx needs for at least the next 12 months.
New Credit Facility Secured Entered five-year, $300.0M Revolving Credit Facility to enhance financial and operational flexibility.
Deferred Revenue Recognition Expect to recognize $54.5M in deferred revenue throughout the remainder of 2025 performance obligations.

同業比較

売上高 (TTM)

Teladoc Health, Inc.TDOC
$2.53B
-2.4%
Guardian Pharmacy Services, Inc.GRDN
$1.39B
+18.7%
Progyny, Inc.PGNY
$1.27B
+11.4%

粗利益率 (最新四半期)

GoodRx Holdings, Inc.GDRX
93.2%
-0.9pp
NovoCure LimitedNVCR
73.2%
-3.9pp
Teladoc Health, Inc.TDOC
70.1%
-1.8pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
EWTX$3.28B-20.8-30.9%0.7%
TXG$2.42B-31.5-10.3%8.5%
IMNM$2.29B-9.8-87.2%1.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-0.7%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月25日
|
EPS:-$0.19
|
売上高:$635.33M
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年10月30日|
    売上高: $626.44M-2.2%
    |
    EPS: $-0.28+40.0%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年7月30日|
    売上高: $631.90M-1.6%
    |
    EPS: $-0.19-96.1%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月1日|
    売上高: $629.37M-2.6%
    |
    EPS: $-0.53+8.2%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月27日|
    売上高: $2.57B-1.3%
    |
    EPS: $-5.87-331.6%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月31日|
    売上高: $640.51M-3.0%
    |
    EPS: $-0.20-42.9%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月1日|
    売上高: $642.44M-1.5%
    |
    EPS: $-4.92+1130.0%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年4月26日|
    売上高: $646.13M+2.7%
    |
    EPS: $-0.49+16.7%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月23日|
    売上高: $2.60B+8.1%
    |
    EPS: $-1.36+98.4%
    予想を下回る